Merck: new treatment option for HIV

(CercleFinance.com) - Merck announces positive data from Phase 3 trials.
These trials showed that the once-daily, two-drug oral doravirin/islatravir (DOR/ISL) regimen maintained HIV-1 viral suppression at week 48.

In both trials, DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with low virologic intensity HIV-1.

Results will be presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Merck expects to submit marketing authorization applications to regulatory agencies by mid-2025.

' Despite the availability of multiple daily antiretroviral treatments, the needs of people living with HIV are evolving. Many people living with HIV are older and also suffer from co-morbidities, making it all the more important to have daily treatment options that can help meet each person's unique health needs', said Professor Chloe Orkin, Dean of Healthcare Transformation at Queen Mary University of London, UK.

' I am delighted to see that DOR/ISL has the potential to become a new daily treatment option for people living with HIV who could benefit from this two-drug regimen. '

Copyright (c) 2025 CercleFinance.com. All rights reserved.